Pacific Biosciences reported a 4% year‑over‑year revenue decline in Q3, missing consensus as instrument sales fell sharply while consumables grew. Management highlighted record consumable revenue and margin improvements but instrument revenue weakness weighed on the quarter amid uneven instrument placements. Separately, Berry Genomics secured China’s NMPA Class III approval for the PacBio Sequel II CNDx sequencer and a thalassemia assay, marking the first regulatory clearance of a clinical‑grade long‑read sequencer in China. Berry plans to expand clinical assays for rare and hereditary disorders on the platform. Taken together, the results and regulatory win illustrate divergent forces in the sequencing sector: short‑term instrument cyclical softness for some vendors while long‑read platforms gain clinical footholds in major markets. For precision‑medicine planners, the Berry clearance signals expanded long‑read diagnostic capabilities in China.